Evaluation of the protective effect of Cystone against cisplatin-induced nephrotoxicity in cancer patients.
Phase 3
- Conditions
- ephrotoxicity induced by medications.Nephropathy induced by other drugs, medicaments and biological substances
- Registration Number
- IRCT2016052724625N2
- Lead Sponsor
- Vice Chancellor for Research of Semnan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Cancer patients assigned to receive cisplatin.
Exclusion criteria:
Receiving of cisplatin in the past; previous history of renal disease; receiving of any medications that have nephrotoxicity effect.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Creatinine. Timepoint: 22 days after intervention. Method of measurement: Laboratory test.
- Secondary Outcome Measures
Name Time Method